Integration of multi-omics data shows downregulation of mismatch repair, purin, and tublin pathways in AR-negative triple-negative chemotherapy-resistant breast tumors
Tang, X.; Thompson, K. J.; Kalari, K. R.; Sinnwell, J. P.; Suman, V.; Vedell, P. T.; McLaughlin, S. A.; Northfelt, D. W.; Moreno Aspitia, A.; Gray, R. J.; Carter, J. M.; Weinshilboum, R.; Wang, L.; Boughey, J. C.; Goetz, M. P.
Show abstract
Triple negative breast cancer (TNBC) patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy (NAC) will likely experience recurrence of the disease within 3-4 years. Prognostic assessment of early recurrence could facilitate clinical decisions and impact disease survival. This study investigated pre- and post-NAC multi-omics data from both an in-house and a public clinical study to identify biomarkers of NAC response. We observed significant transcriptional differences associated with response in the residual disease (post-NAC biopsies), which did not exist in the pre-NAC biopsies. We further refined the post-NAC transcriptional changes to a 17-gene signature and machine learning models were applied to evaluate the signatures diagnostic potential (area under the curve [≥] 0.8). Interestingly, the signature was enriched with down-regulated immune genes and several of these genes demonstrated prognostic potential in basal TNBC tumors. Our 17-gene signature provides additional insight into TNBC recurrence, which warrants further investigation.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Clustering of HR+/HER2- breast cancer in an Asian cohort is driven by immune phenotypes 96%
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy 95%
- Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer 95%
Similar papers in this journal
- RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer 97%
- A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death 96%
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 95%
Similar papers in this journal
- Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer 95%
- Germline genomic landscapes of breast cancer patients significantly predict clinical outcomes 94%
- Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma 92%
Similar papers in this journal
- ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastrophe 94%
- CD4+ T-cells sensitize quasi-mesenchymal breast tumors lacking CD73 to anti-CTLA4 immune checkpoint blockade therapy 92%
- Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanoma 91%
Similar papers in this journal
- NDRG1 expression is an independent prognostic factor in inflammatory breast cancer 95%
- The prognostic value of lymph node involvement after neoadjuvant chemotherapy is different among breast cancer subtypes 94%
- Protein profiling of breast carcinomas reveals expression of immune-suppressive factors and signatures relevant to patient outcome 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.